Analysts Set Beta Bionics, Inc. (NASDAQ:BBNX) Target Price at $20.10

Beta Bionics, Inc. (NASDAQ:BBNX) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $20.10.

Several brokerages have recently issued reports on BBNX. Truist Financial upped their target price on shares of Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Bank of America reduced their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. UBS Group initiated coverage on Beta Bionics in a research report on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Beta Bionics in a research note on Friday, July 17th. Finally, Leerink Partners reduced their target price on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd.

Beta Bionics Price Performance

Beta Bionics stock opened at $15.90 on Monday. Beta Bionics has a twelve month low of $8.80 and a twelve month high of $32.71. The company has a market capitalization of $715.34 million, a P/E ratio of -9.64 and a beta of 3.13. The stock’s 50 day moving average is $15.24 and its 200 day moving average is $13.06.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million during the quarter. As a group, equities analysts expect that Beta Bionics will post -2.1 EPS for the current year.

Insider Activity at Beta Bionics

In related news, Director Christy Jones sold 2,811 shares of Beta Bionics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $14.00, for a total value of $39,354.00. Following the completion of the sale, the director directly owned 27,400 shares in the company, valued at approximately $383,600. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Hopman sold 5,329 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $67,198.69. Following the completion of the transaction, the insider directly owned 130,887 shares of the company’s stock, valued at approximately $1,650,485.07. This trade represents a 3.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 40,351 shares of company stock valued at $553,961 over the last three months. 5.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BBNX. Summit Securities Group LLC bought a new stake in Beta Bionics in the 4th quarter worth approximately $52,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the period. Strs Ohio purchased a new position in shares of Beta Bionics in the 1st quarter worth $29,000. Legal & General Group Plc boosted its stake in shares of Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after buying an additional 2,639 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Beta Bionics by 630,000.0% in the fourth quarter. CIBC Private Wealth Group LLC now owns 6,301 shares of the company’s stock worth $192,000 after acquiring an additional 6,300 shares during the period.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.